NCT03171415View on ClinicalTrials.gov

Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

December 28, 2018

Study Completion Date

December 28, 2018

Conditions
ObesityWeight LossOverweight and Obesity
Interventions
DRUG

RZL-012

Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.

DRUG

Placebo

Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.

Trial Locations (1)

53095

Spaulding Clinical, West Bend

All Listed Sponsors
collaborator

Spaulding Clinical Research LLC

OTHER

lead

Raziel Therapeutics Ltd.

INDUSTRY

NCT03171415 - Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers | Biotech Hunter | Biotech Hunter